Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The demand for an effective malaria vaccine is high, with millions of people being affected by the disease every year. A large variety of potential vaccines are under investigation worldwide, and when tested in clinical trials, researchers need to extract as much data as possible from every vaccinated and control volunteer. The use of quantitative real-time polymerase chain reaction (PCR), carried out in real-time during the clinical trials of vaccines designed to act against the liver stage of the parasite's life cycle, provides more information than the gold standard method of microscopy alone and increases both safety and accuracy. PCR can detect malaria parasites in the blood up to 5 days before experienced microscopists see parasites on blood films, with a sensitivity of 20 parasites/mL blood. This PCR method has so far been used to follow 137 vaccinee and control volunteers in Phase IIa trials in Oxford and on 220 volunteer samples during a Phase IIb field trial in The Gambia.

Original publication

DOI

10.4269/ajtmh.2005.73.191

Type

Journal article

Journal

The American journal of tropical medicine and hygiene

Publication Date

07/2005

Volume

73

Pages

191 - 198

Addresses

Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.

Keywords

Animals, Humans, Anopheles, Plasmodium, Malaria, RNA, Ribosomal, 18S, DNA Primers, Malaria Vaccines, Sensitivity and Specificity, Reproducibility of Results, Polymerase Chain Reaction, Base Sequence, Clinical Trials as Topic